From €1417EUR$1,500USD£1,205GBP
- Report
- April 2024
- 80 Pages
United Kingdom
From €1417EUR$1,500USD£1,205GBP
- Report
- April 2024
- 80 Pages
Vietnam
From €1417EUR$1,500USD£1,205GBP
- Drug Pipelines
- February 2019
- 300 Pages
Global
From €20776EUR$22,000USD£17,681GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €472EUR$500USD£402GBP
- Report
- March 2022
- 270 Pages
Global
From €3506EUR$3,712USD£2,983GBP
Namenda (memantine) is a drug used to treat moderate to severe Alzheimer's disease and other forms of dementia. It is a centrally acting NMDA receptor antagonist, which works by blocking the action of glutamate, a neurotransmitter that is thought to be involved in the development of Alzheimer's disease. Namenda is the only drug approved by the FDA for the treatment of moderate to severe Alzheimer's disease. It is also used off-label to treat other forms of dementia, such as vascular dementia and Lewy body dementia.
Namenda is part of a larger market of Central Nervous System (CNS) drugs, which includes drugs used to treat a variety of neurological conditions, such as depression, anxiety, epilepsy, and Parkinson's disease. CNS drugs are typically prescribed by neurologists and psychiatrists, and are often used in combination with other medications.
Some companies in the Namenda market include Allergan, Lundbeck, and Otsuka Pharmaceuticals. Show Less Read more